Market Research Logo

Global Chronic Kidney Disease (CKD) Drugs Market Forecast 2018-2028

Global Chronic Kidney Disease (CKD) Drugs Market Forecast 2018-2028

The Global Chronic Kidney Disease (CKD) Drugs market reached $12.2bn in 2016 and is expected to grow at a CAGR of 3.9% in the first half of the forecast period. The market is dominated by calcium channel blockers and ACE inhibitors.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 171-page report you will receive 85 tables and 93 figures – all unavailable elsewhere.

The 171-page report provides clear detailed insight into the Global Chronic Kidney Disease (CKD) Drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global Chronic Kidney Disease (CKD) Drugs market forecasts from 2018-2028
  • This report also breaks down the revenue forecast for the Global Chronic Kidney Disease (CKD) Drugs market by drug class:
  • ACE inhibitors
  • Angiotensin-II receptor blockers
  • Calcium channel blockers
  • Beta blockers: BREVIBLOC, Bystolic
  • Erythropoiesis-stimulating agents (ESAs)
  • Diuretics
  • Others
This report provides a SWOT Analysis for each drug class.
  • This report provides revenue forecast for these leading drugs:
  • Aceon
  • Lisinopril
  • Losartan
  • AVAPRO
  • Twynsta
  • BREVIBLOC
  • Bystolic
  • Mircera
  • Epoetin Alfa BS
  • Natrilix SR
  • Spironolactone
  • Urief
  • AURYXIA
  • This report also breaks down the revenue forecast for the Global Chronic Kidney Disease (CKD) Drugs market by distribution channel:
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Others
  • This report also breaks down the revenue forecast for the Global Chronic Kidney Disease (CKD) Drugs market by regional and national market:
  • North America: US and Canada
  • Europe: Germany, the UK, France, Spain, Italy, Rest of Europe
  • Asia-Pacific: Japan, China, India, Rest of Asia-Pacific
  • Latin America: Brazil, Mexico, Rest of Latin America
  • Middle East & Africa: Saudi Arabia, South of Africa, Rest of MEA
Each regional market is further broken down by drug class and distribution channel.
  • This report provides company overview, financial information, product portfolio and recent developments for the leading companies in the Global Chronic Kidney Disease (CKD) Drugs market:
  • Pfizer, Inc.
  • Amgen
  • Roche
  • GlaxoSmithKline (GSK)
  • Allergan
  • AbbVie
  • Kissei Pharmaceutical Co., Ltd.
Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.


1. Report Overview
1.1 Global Chronic Kidney Disease Drugs Market Overview
1.2 Overview of Findings
1.3 Structure of the Report
1.4 Global Chronic Kidney Disease Drugs Market Segmentation
1.5 Why You Should Read This Report
1.6 How This Report Delivers
1.7 Key Questions Answered by This Analytical Report
1.8 Who is This Report For?
1.9 Methodology
1.10 Associated Visiongain Reports
1.11 About Visiongain
2. Introduction to Chronic Kidney Disease Drugs
2.1 An Introduction to Chronic Kidney Disease Drugs
2.2. ACE Inhibitors
2.3. Angiotensin-II Receptor Blockers
2.4. Calcium Channel Blockers
2.5. Beta Blockers
2.6. Erythropoiesis-stimulating agents (ESAs)
2.7. Diuretics
2.8. Drivers
2.8.1. High Prevalence of Chronic Kidney Disease (CKD) Worldwide
2.8.2. Rise in Incidence of Cardiovascular Disorders and Diabetes
2.9. Restraints
2.9.1 Competition from Biosimilars Due to Patent Loss
3. Global Chronic Kidney Disease Drugs Market by Product Type 2018-2028
3.1 Global Chronic Kidney Disease Drugs Market Forecast 2018-2028
3.2 Changing Market Shares by Drug Class 2018-2028
3.3. Global ACE Inhibitors Market: Sales Forecast 2018-2028
3.3.1. Aceon (Abbott Laboratories)
3.3.2. Lisinopril (GlaxoSmithKline plc.)
3.3.3. SWOT Analysis of the ACE Inhibitors Market, 2018-2028
3.3.3.1. Strength
3.3.3.1.1. Advantages of ACE Inhibitors drugs
3.3.3.2. Weakness
3.3.3.2.1. Side effect of ACE Inhibitors
3.3.3.3. Opportunity
3.3.3.3.1. Increasing prevalence of cardiovascular disease
3.3.3.4. Threat
3.3.3.4.1. Competitive and Fragmented market
3.4. Global Angiotensin-II Receptor Blockers Market: Sales Forecast 2018-2028
3.4.1. Losartan (Morepen Laboratories Ltd.)
3.4.2. AVAPRO (Sanofi S.A.)
3.4.3. SWOT Analysis of the Angiotensin-II Receptor Blockers Market, 2018-2028
3.4.3.1. Strength
3.4.3.1.1. Blood pressure lowering efficacy in patients with hypertension
3.4.3.2. Weakness
3.3.3.2.1. Side effects during pregnancy
3.4.3.3. Opportunity
3.4.3.3.1. Increasing prevalence of Diabetic Kidney Disease
3.4.3.4. Threat
3.4.3.4.1. Fewer interactions with other drugs
3.5 Global Calcium Channel Blockers Market: Sales Forecast 2018-2028
3.5.1. Norvasc (Pfizer Inc.)
3.5.2. Twynsta (Boehringer Ingelheim Pharmaceuticals, Inc.)
3.5.3. SWOT Analysis of the Calcium Channel Blockers Market, 2018-2028
3.5.3.1. Strength
3.5.3.1.1. Favourable Reimbursement Scenario
3.5.3.2. Weakness
3.5.3.2.1. Side effect of Calcium Channel Blockers
3.5.3.3. Opportunity
3.5.3.3.1. Rising prevalence of hypertension across the globe
3.5.3.4. Threat
3.5.3.4.1. Availability of cost effective biosimilars
3.6. Global Beta Blockers Market: Sales Forecast 2018-2028
3.6.1. BREVIBLOC (Baxter International Inc.)
3.6.2. Bystolic (ALLERGAN)
3.6.3. SWOT Analysis of the Beta Blockers Market, 2018-2028
3.6.3.1. Strength
3.6.3.1.1. Advantages of Beta Blockers
3.6.3.2. Weakness
3.6.3.2.1. Can’t be used by Diabetes Patients
3.6.3.3. Opportunity
3.6.3.3.1. Increasing prevalence of heart failure
3.6.3.4. Threat
3.6.3.4.1. Availability of cost effective biosimilars
3.7. Global Erythropoiesis-stimulating agents (ESAs) Market: Sales Forecast 2018-2028
3.7.1. Mircera (F. Hoffmann-La Roche AG)
3.7.2. Epoetin Alfa BS (Japan Chemical Research Pharmaceuticals Co., Ltd.)
3.7.3. SWOT Analysis of the Erythropoiesis-stimulating agents (ESAs) Market, 2018-2028
3.7.3.1. Strength
3.7.3.1.1. Mircera launched in the U.S.
3.7.3.2. Weakness
3.7.3.2.1. Mircera is not a preferred brand of the Payers
3.7.3.3. Opportunity
3.7.3.3.1. Increased incidences of kidney failures
3.7.3.4. Threat
3.7.3.4.1. Availability of cost effective biosimilars
3.8. Global Diuretics Market: Sales Forecast 2018-2028
3.8.1. Natrilix SR (Serdia Pharmaceuticals Pvt. Ltd.)
3.8.2. Spironolactone (Pfizer, Inc.)
3.8.3. SWOT Analysis of the Diuretics Market, 2018-2028
3.8.3.1. Strength
3.8.3.1.1. Reduces Risk of Congestive heart Failure Hospitalization
3.8.3.2. Weakness
3.8.3.2.1. Can Cause Heart Rhythm Problems
3.8.3.3. Opportunity
3.8.3.3.1. Increasing prevalence of Congestive Heart Failure
3.8.3.4. Threat
3.8.3.4.1. Generic Competition
3.9. Global Others Market: Sales Forecast 2018-2028
3.9.1. Urief (Kissei Pharmaceutical Co., Ltd., Eisai Co., Ltd)
3.9.2. AURYXIA (Keryx Biopharmaceuticals, Inc.)
4. Global Chronic Kidney Disease Drugs Market by Distribution Channel 2018-2028
4.1 Global Chronic Kidney Disease Drugs Market Forecast by Distribution Channel 2018-2028
4.1.1. Hospital Pharmacies
4.1.2. Retail Pharmacies
4.1.3. Online Pharmacies
4.1.4. Others (Clinics, Supermarket Drug Stores, etc.)
5. Leading National Markets 2018-2028
5.1. Geographical Breakdown of the World Chronic Kidney Disease Drugs Market
5.2 Chronic Kidney Disease Drugs Market: Regional Market Forecast 2018-2028
5.2.1 How Will Regional Market Shares Change to 2028?
6. North America Chronic Kidney Disease Drugs Market 2018-2028
6.1. U.S. Chronic Kidney Disease Drugs Market: Trends and Developments
6.2. Canada Chronic Kidney Disease Drugs Market: Trends and Developments
7. Europe Chronic Kidney Disease Drugs Market 2018-2028
7.1. Germany Chronic Kidney Disease Drugs Market Forecast 2018-2028
7.2. France Chronic Kidney Disease Drugs Market Forecast 2018-2028
7.3. U.K. Chronic Kidney Disease Drugs Market Forecast 2018-2028
7.4. Italy Chronic Kidney Disease Drugs Market Forecast 2018-2028
7.5. Spain Chronic Kidney Disease Drugs Market Forecast 2018-2028
7.6. Rest of Europe Chronic Kidney Disease Drugs Market Forecast 2018-2028
8. Asia-Pacific Chronic Kidney Disease Drugs Market 2018-2028
8.1. China Chronic Kidney Disease Drugs Market: Trends and Developments
8.2. Japan Chronic Kidney Disease Drugs Market: Trends and Developments
8.3. India Chronic Kidney Disease Drugs Market: Trends and Developments
8.4. Rest of Asia-Pacific Chronic Kidney Disease Drugs Market: Trends and Developments
9. Latin America Chronic Kidney Disease Drugs Market 2018-2028
9.1 Brazil Chronic Kidney Disease Drugs Market: Trends and Developments
9.2. Mexico Chronic Kidney Disease Drugs Market: Trends and Developments
9.3. Rest of Latin America Chronic Kidney Disease Drugs Market: Trends and Developments
10. Middle East & Africa Chronic Kidney Disease Drugs Market 2018-2028
10.1. Saudi Arabia Chronic Kidney Disease Drugs Market Forecast 2018-2028
10.2. South Africa Chronic Kidney Disease Drugs Market Forecast 2018-2028
10.3. Rest of Middle East & Africa Chronic Kidney Disease Drugs Market Forecast 2018-2028
11. Leading Companies in the Chronic Kidney Disease Drugs
11.1. Sanofi S.A.
11.1.1 Sanofi S.A.: Chronic Kidney Disease Drugs Portfolio
11.1.2 Sanofi S.A.: Financial Overview
11.1.3 Sanofi S.A.: Recent Developments
11.2. Pfizer, Inc.
11.2.1 Pfizer, Inc.: Chronic Kidney Disease Drugs Portfolio
11.2.2 Pfizer, Inc.: Financial Overview
11.2.3 Pfizer, Inc.: Recent Developments
11.3. Amgen, Inc.
11.3.1 Amgen, Inc.: Chronic Kidney Disease Drugs Portfolio
11.3.2 Financial Overview
11.3.3. Recent Transactions Summary
11.4. F. Hoffmann-La Roche AG
11.4.1 Roche: Chronic Kidney Disease Drugs Portfolio
11.4.2 Roche: Financial Overview
11.4.3. Recent Transactions Summary
11.5. GlaxoSmithKline plc
11.5.1 GlaxoSmithKline plc: Chronic Kidney Disease Drugs Portfolio
11.5.2 GlaxoSmithKline plc: Financial Overview
11.5.3 GlaxoSmithKline plc: Recent Transactions Summary
11.6. Allergan plc
11.6.1 Allergan plc: Chronic Kidney Disease Drugs Portfolio
11.6.2 Allergan plc: Financial Overview
11.6.3 Allergan plc: Recent Transactions Summary
11.7. AbbVie Inc.
11.7.1 AbbVie Inc.: Chronic Kidney Disease Drugs Portfolio
11.7.2 AbbVie Inc.: Financial Overview
11.7.3 AbbVie Inc.: Recent Transactions Summary
11.8. Kissei Pharmaceutical Co., Ltd
11.8.1 Kissei Pharmaceutical Co., Ltd.: Chronic Kidney Disease Drugs Portfolio
11.8.2 Kissei Pharmaceutical Co., Ltd.: Financial Overview
11.8.3 Kissei Pharmaceutical Co., Ltd.: Recent Transactions Summary
12. Conclusions
12.1 The World Chronic Kidney Disease Drugs Market in 2016 and 2017
12.1.1 Current Leading Chronic Kidney Disease Drugs Segments
12.1.2 Leading Regional Markets
12.2 World Chronic Kidney Disease Drugs Market Forecast 2017-2027
12.3 The Future of the Military Medical & Humanitarian Trauma Care Market?
Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Tables
Table 3.1 Global Chronic Kidney Disease Drugs Market by Drugs Class: Revenue ($m) and Market Share (%), 2016
Table 3.2 Global Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.3 Global ACE Inhibitors Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.4 Global Aceon Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.5 Global Lisinopril Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.6 SWOT Analysis of the ACE Inhibitors Market, 2018-2028
Table 3.7 Global Angiotensin-II Receptor Blockers Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.8 Global Losartan Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.9 Global AVAPRO Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.10 SWOT Analysis of the Angiotensin-II Receptor Blockers Market, 2018-2028
Table 3.11 Global Calcium Channel Blockers Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.12 Global Norvasc Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.13 Global Twynsta Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.14 SWOT Analysis of the Calcium Channel Blockers Market, 2018-2028
Table 3.15 Global Beta Blockers Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.16 Global BREVIBLOC Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.17 Global Bystolic Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.18 SWOT Analysis of the Beta Blockers Market, 2018-2028
Table 3.19 Global Erythropoiesis-stimulating agents (ESAs) Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.20 Global Mircera Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.21 Global Epoetin Alfa BS Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.22 SWOT Analysis of the Erythropoiesis-stimulating agents (ESAs) Market, 2018-2028
Table 3.23 Global Diuretics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.24 Global Natrilix SR Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.25 Global Spironolactone Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.26 SWOT Analysis of the Diuretics Market, 2018-2028
Table 3.27 Global Others Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.28 Global Urief Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 3.29 Global AURYXIA Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 4.1 Global Chronic Kidney Disease Drugs Market Forecast, by Distribution Channel Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 4.2 Global Hospital Pharmacies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 4.3 Global Retail Pharmacies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 4.4 Global Online Pharmacies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 4.5 Global Others Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 5.1 Global Chronic Kidney Disease Drugs Market by Region: Revenue ($m), 2016 and 2017
Table 5.2 Global Chronic Kidney Disease Drugs Market Forecast, by Region: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 6.1 North America Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 6.2 North America Chronic Kidney Disease Drugs Market Forecast, by Distribution Channel Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 6.3 North America Chronic Kidney Disease Drugs Market Forecast, by End User: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 6.4 U.S. Chronic Kidney Disease Drugs Market Forecast, by End User: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 6.5 Canada Chronic Kidney Disease Drugs Market Forecast, by End User: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 7.1 Europe Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 7.2 Europe Chronic Kidney Disease Drugs Market Forecast, by Distribution Channel Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 7.3 Europe Chronic Kidney Disease Drugs Market Forecast, by Country: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 7.4 Germany Chronic Kidney Disease Drugs Market Forecast, 2016-2028 ($m, AGR %, CAGR %)
Table 7.5 France Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 7.6 U.K. Chronic Kidney Disease Drugs Market Forecast, 2016-2028 ($m, AGR %, CAGR %)
Table 7.7 Italy Chronic Kidney Disease Drugs Market Forecast, 2016-2028 ($m, AGR %, CAGR %)
Table 7.8 Spain Chronic Kidney Disease Drugs Market Forecast, 2016-2028 ($m, AGR %, CAGR %)
Table 7.9 Rest of Europe Chronic Kidney Disease Drugs Market Forecast, 2016-2028 ($m, AGR %, CAGR %)
Table 8.1 Asia-Pacific Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 8.2 Asia-Pacific Chronic Kidney Disease Drugs Market Forecast, by Distribution Channel Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 8.3 Asia-Pacific Chronic Kidney Disease Drugs Market Forecast, By Country: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 8.4 China Chronic Kidney Disease Drugs Market Forecast, 2016-2028 ($m, AGR %, CAGR %)
Table 8.5 Japan Chronic Kidney Disease Drugs Market Forecast, 2016-2028 ($m, AGR %, CAGR %)
Table 8.6 India Chronic Kidney Disease Drugs Market Forecast, 2016-2028 ($m, AGR %, CAGR %)
Table 8.7 Rest of Asia-Pacific Chronic Kidney Disease Drugs Market Forecast, 2016-2028 ($m, AGR %, CAGR %)
Table 9.1 Latin America Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 9.2 Latin America Chronic Kidney Disease Drugs Market Forecast, by Distribution Channel Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 9.3 Latin America Chronic Kidney Disease Drugs Market Forecast, by Country: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 9.4 Brazil Chronic Kidney Disease Drugs Market Forecast, 2016-2028 ($m, AGR %, CAGR %)
Table 9.5 Mexico Chronic Kidney Disease Drugs Market Forecast, 2016-2028 ($m, AGR %, CAGR %)
Table 9.6 Rest of Latin America Chronic Kidney Disease Drugs Market Forecast, 2016-2028 ($m, AGR %, CAGR %)
Table 10.1 Middle East & Africa Chronic Kidney Disease Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 10.2 Middle East & Africa Chronic Kidney Disease Drugs Market Forecast, by Distribution Channel Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 10.3 Middle East & Africa (MEA) Chronic Kidney Disease Drugs Market Forecast, by Country: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 10.4 Saudi Arabia Chronic Kidney Disease Drugs Market Forecast, by Country: Revenues ($m), AGR (%), CAGR (%), 2016-2028
Table 10.5 South Africa Chronic Kidney Disease Drugs Market Forecast, 2016-2028 ($m, AGR %, CAGR %)
Table 10.6 Rest of MEA Chronic Kidney Disease Drugs Market Forecast, 2016-2028 ($m, AGR %, CAGR %)
Table 11.1 Sanofi S.A.: Overview, 2017
Table 11.2 Sanofi S.A.: Revenue ($m), AGR (%), 2012-2016
Table 11.3 Pfizer, Inc.: Overview, 2017
Table 11.4 Pfizer, Inc.: Revenue ($m), AGR (%), 2012-2016
Table 11.5 Amgen, Inc. Corporation: Overview, 2017
Table 11.6 Amgen, Inc.: Revenue ($m), AGR (%), 2012-2016
Table 11.7 Roche: Overview, 2017
Table 11.8 Roche: Revenue ($m), AGR (%), 2012-2016
Table 11.9 GlaxoSmithKline plc: Overview, 2017
Table 11.10 GlaxoSmithKline plc: Revenue ($m), AGR (%), 2012-2016
Table 11.11 Allergan plc: Overview, 2017
Table 11.12 Allergan plc: Revenue ($m), AGR (%), 2012-2016
Table 11.13 AbbVie Inc.: Overview, 2017
Table 11.14 AbbVie Inc.: Revenue ($m), AGR (%), 2012-2016
Table 11.15 Kissei Pharmaceutical Co., Ltd: Overview, 2017
Table 11.16 Kissei Pharmaceutical Co., Ltd: Revenue ($m), AGR (%), 2013-2017
List of Figure

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report